Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18596683 | PEPTIDE BIOMARKER FOR IDENTIFYING HIPPOCAMPUS SPECIES BASED ON PEPTIDOMICS AND APPLICATION THEREOF | March 2024 | April 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18402122 | BIOPLASTIC PRODUCTION METHOD | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18373435 | Caproate-producing bacterium with multiple substrate utilization capabilities and its applications | September 2023 | July 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18461008 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND EXOSPORIUM FRAGMENTS FOR PEST CONTROL AND PLANT HEALTH | September 2023 | September 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18350668 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURONAL INJURIES | July 2023 | December 2025 | Abandon | 30 | 2 | 0 | No | No |
| 18012660 | METHOD AND SYSTEM FOR COLONY PICKING | December 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18009395 | PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS | December 2022 | November 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17998345 | AN ANTIBODY FRAGMENT BASED ANTIMICROBIAL CONJUGATE SELECTIVELY TARGETING PSEUDOMONAS | November 2022 | December 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17907449 | MICROBIOME-BASED THERAPEUTICS | September 2022 | March 2026 | Abandon | 42 | 2 | 0 | No | No |
| 17814459 | PROBIOTIC STRAIN FOR REDUCING SERUM URIC ACID, COMPOSITION AND USE THEREOF | July 2022 | January 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17844835 | OPTOGENETIC CONTROL OF MICROBIAL CO-CULTURE POPULATIONS | June 2022 | September 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17748727 | REAGENT KIT CONTAINING POLYPEPTIDE FOR USE IN DETECTION OF INTERMOLECULAR INTERACTIONS | May 2022 | December 2025 | Allow | 43 | 5 | 1 | Yes | No |
| 17661169 | BIOPLASTIC PRODUCTION METHOD | April 2022 | August 2025 | Abandon | 40 | 5 | 1 | Yes | No |
| 17770740 | MICROBIOTA BASED THERAPIES TO PROMOTE MENTAL HEALTH | April 2022 | March 2026 | Abandon | 47 | 2 | 1 | No | No |
| 17717211 | Method for Preparing Bacterial Cellulose Membrane Using Enzymatic Soybean Hydrolysate | April 2022 | July 2025 | Abandon | 39 | 2 | 0 | No | No |
| 17696374 | Uricase Derivative Co-conjugated With Fatty acid-linked PEG and optionally, Alkoxy PEG | March 2022 | May 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17678441 | METHOD FOR MICROALGAL CULTIVATION | February 2022 | August 2024 | Abandon | 30 | 3 | 0 | No | No |
| 17666345 | PHOTOSYNTHETIC PROTEIN SECRETION PLATFORM | February 2022 | August 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17560060 | PREOPERATIVE COMPOSITIONS AND METHODS OF PREPARATION THEREOF | December 2021 | May 2025 | Allow | 40 | 4 | 1 | Yes | No |
| 17551057 | COMPOSITIONS AND METHODS OF TREATING ASTHMA | December 2021 | March 2025 | Abandon | 39 | 3 | 1 | No | No |
| 17530649 | COMPOSITIONS AND METHODS RELATED TO GROWING AND/OR PRODUCING BACTERIAL STRAINS USING AGRICULTURAL BYPRODUCTS | November 2021 | March 2025 | Abandon | 39 | 4 | 1 | No | No |
| 17524568 | SPECIMEN COLLECTION FOR MICROBIAL BURDEN CLASSIFICATION AND SPECIMEN TRANSPORTATION TO LAB FOR REPORTING DIRECT-FROM-SPECIMEN ID AND AST | November 2021 | November 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17606177 | USES OF PANTOTHENIC ACID IN PREPARATION OF A COMPOSITION FOR TREATING AND/OR PREVENTING TUMORS | October 2021 | March 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17508562 | MEDIUM FOR PRIMARY ISOLATION OF PORPHYROMONAS GINGIVALIS, AND A MEDIUM FOR PREPARING THE MEDIUM AND USE THEREOF | October 2021 | May 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17436070 | FERRITIN NANOCAGE FOR MULTI-DISPLAYING TRAIL TRIMER AND CANCER-TARGETING PEPTIDE AND USE THEREOF AS ANTICANCER AGENT | September 2021 | February 2026 | Allow | 53 | 4 | 1 | No | No |
| 17419082 | Polypeptide Having Phospholipase C Activity and Use Thereof | June 2021 | November 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17358945 | Novel Methods | June 2021 | February 2026 | Abandon | 56 | 4 | 1 | No | Yes |
| 17413179 | A METHOD FOR INCREASING ROMIDEPSIN PRODUCTION FROM FERMENTATION BROTH | June 2021 | January 2026 | Allow | 56 | 5 | 1 | Yes | No |
| 17331613 | PREOPERATIVE COMPOSITIONS AND METHODS OF PREPARATION THEREOF | May 2021 | November 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17324067 | ONE-STEP FORMULATION FOR ALL-IN-ONE HYDROLYSIS SOLUTION | May 2021 | August 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17292266 | BIOSYNTHESIS OF MOGROSIDES | May 2021 | October 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17291058 | PROCESSES FOR TREATMENT OF MICROBE SUSPENSIONS | May 2021 | June 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17244385 | COMPOSITIONS CONTAINING ARGINASE 1 FOR THE TREATMENT OF NEUROVASCULAR AND RETINAL VASCULAR DISORDERS | April 2021 | September 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17238641 | SYSTEMS AND METHODS FOR OPTIMIZATION OF ENZYMES | April 2021 | December 2024 | Abandon | 44 | 3 | 1 | No | Yes |
| 17283299 | MUTANT STRAIN OF TRICHODERMA REESEI, AND PROTEIN MANUFACTURING METHOD | April 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17210956 | METHOD FOR MEASURING A BLOOD COAGULATION ACTIVITY | March 2021 | October 2025 | Abandon | 54 | 5 | 0 | Yes | No |
| 17278662 | STRAIN FOR PREVENTING AND TREATING METABOLIC DISEASES AND USE THEREOF | March 2021 | March 2024 | Allow | 36 | 2 | 0 | Yes | No |
| 17209318 | SYSTEMS AND METHODS FOR BIOMASS CARBON REMOVAL AND STORAGE | March 2021 | May 2023 | Abandon | 25 | 3 | 0 | No | No |
| 17276222 | PRODUCTION METHOD FOR IMMOBILIZED MICROORGANISMS AND PRODUCTION METHOD FOR AMINO ACID USING THE SAME | March 2021 | June 2024 | Abandon | 39 | 2 | 1 | Yes | No |
| 17276075 | A COMPOSITION OF PHOTOAUTOTROPHIC MICROORGANISMS AND CHEMOHETEROTROPHIC MICROORGANISMS IN A BIOFILM | March 2021 | January 2025 | Allow | 46 | 3 | 1 | Yes | No |
| 17273580 | NOVEL TREATMENT FOR MUCOSITIS | March 2021 | February 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17273635 | PROBIOTIC COMBINATION FOR TREATMENT OF INFLAMMATORY-RELATED GASTROINTESTINAL DISORDERS | March 2021 | August 2025 | Abandon | 54 | 6 | 1 | No | Yes |
| 17187499 | COMPOSITION CONTAINING A VITAL PROBIOTIC CULTURE FOR HUMAN OR VETERINARY USE AS A DEODORANT | February 2021 | January 2025 | Abandon | 47 | 5 | 0 | No | No |
| 17267877 | BEHAVIOURAL TREATMENT | February 2021 | March 2025 | Abandon | 49 | 3 | 1 | No | No |
| 17172860 | COMPOSITIONS COMPRISING PROBIOTICS AND METHODS OF USE THEREOF | February 2021 | August 2023 | Abandon | 30 | 4 | 1 | No | No |
| 17168328 | METHOD OF IDENTIFYING PROPERTIES OF MICROORGANISMS USING ODEP FORCE | February 2021 | April 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17265829 | Directed Evolution of a Mutualistic Community of Organisms for the Production of a Nutrient or a Nutraceutical | February 2021 | January 2025 | Abandon | 47 | 4 | 0 | No | No |
| 17151871 | BIOSYNTHESIS AND RECOVERY OF SECONDARY METABOLITES | January 2021 | January 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17147709 | METHODS AND COMPOSITIONS FOR RESECTION MARGIN LAVAGE | January 2021 | April 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17144868 | INTESTINAL MICROBE HAVING D-PSICOSE-RESPONSIVE PROLIFERATION | January 2021 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17258195 | USE OF LEUCONOSTOC MESENTEROIDES SUBSP. MESENTEROIDES SD23 FOR MATERNAL FETAL METABOLIC PROGRAMMING | January 2021 | April 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17257156 | MICROCAPSULE OF SUSTAINABLE SELF-HEALING COAL MINE VENTILATION SEALING MATERIAL CRACK AND PREPARATION METHOD THEREOF | December 2020 | December 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17256599 | SEPARATING AGENT | December 2020 | June 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17130118 | USE OF GRAM-NEGATIVE LYSIN-ANTIMICROBIAL PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTS IN TREATING ENDOCARDITIS | December 2020 | May 2024 | Abandon | 41 | 3 | 1 | No | No |
| 17126346 | Microbial Conductive Ceramics and Preparation Method and Application thereof | December 2020 | March 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17121685 | WOUND CLOSURE ENHANCEMENT METHODS AND MATERIALS VIA MANIPULATION OR AUGMENTATION OF LIPIN-1 | December 2020 | January 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17117099 | ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF | December 2020 | June 2025 | Allow | 54 | 6 | 1 | Yes | No |
| 16972492 | COMPOSITION FOR DIAGNOSING DISEASES ASSOCIATED WITH COX2 OVEREXPRESSION AND SCREENING METHOD THEREFOR | December 2020 | March 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 15734900 | COMPOSITION FOR THE TREATMENT OF ATOPIC DERMATITIS COMPRISING BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS LM1017 | December 2020 | March 2023 | Allow | 27 | 2 | 0 | Yes | No |
| 17100005 | CRYPTIC ANTIBIOTICS AND METHODS FOR DETECTING BIOACTIVE CRYPTIC METABOLITES | November 2020 | June 2025 | Allow | 55 | 5 | 1 | Yes | No |
| 17057609 | METHOD FOR PREPARING PRECURSOR OF RECOMBINANT HUMAN INSULIN OR ANALOGUE THEREOF | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17078883 | COMPOSITIONS FOR ACTIVE IMMUNOTHERAPY | October 2020 | June 2025 | Abandon | 56 | 3 | 1 | No | No |
| 17038229 | AUTOMATED BIONANOCATALYST PRODUCTION | September 2020 | October 2025 | Abandon | 60 | 3 | 1 | No | No |
| 17036526 | AUTOTRANSPORTER-MEDIATED DISPLAY OF COMPLEMENT RECEPTOR LIGANDS BY BACTERIAL IMMUNOGENS | September 2020 | January 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17006334 | SALT FORMULATIONS FOR THE FERMENTATION OF MARINE MICROORGANISMS | August 2020 | June 2025 | Abandon | 58 | 4 | 1 | Yes | No |
| 16937051 | SCREENING METHOD, DEVICE AND KIT FOR DETECTING MUCOSAL CARBOHYDRATES AND ASSOCIATED CONDITIONS | July 2020 | December 2024 | Abandon | 53 | 4 | 0 | No | No |
| 16863603 | RAPID METHODS FOR DETERMINING MICROORGANISM GROWTH IN SAMPLES OF HUMAN ORIGIN | April 2020 | August 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16779327 | Targetable 3`-Overhang Nuclease Fusion Proteins | January 2020 | December 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16632966 | METHOD FOR RAPID DETECTION AND ENUMERATION OF VIRUSES, BACTERIOPHAGE AND/OR BACTERIA | January 2020 | July 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16672152 | METHODS FOR DIAGNOSING, MONITORING AND MITIGATING MICROBIOLOGICALLY INFLUENCED CORROSION | November 2019 | April 2023 | Abandon | 41 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BREEN, KIMBERLY CATHERINE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BREEN, KIMBERLY CATHERINE works in Art Unit 1657 and has examined 52 patent applications in our dataset. With an allowance rate of 25.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner BREEN, KIMBERLY CATHERINE's allowance rate of 25.0% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BREEN, KIMBERLY CATHERINE receive 2.46 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BREEN, KIMBERLY CATHERINE is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +72.2% benefit to allowance rate for applications examined by BREEN, KIMBERLY CATHERINE. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 9.3% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.0% of cases where such amendments are filed. This entry rate is in the 24% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 90.9% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.